Hyundai Motor, Boston Dynamics collaboration takes shape… target price 100ten thousand won
Reports say Hyundai Motor has entered a phase of fleshing out its collaboration with Boston Dynamics, and some securities firms have set a target price for Hyundai Motor at 100ten thousand won. Hanmi Pharmaceutical’s R&D competitiveness has come into focus following a technology transfer, prompting securities firms to raise their target prices. The outlook for Hyundai Mobis’s actuator business has been viewed positively.
Hanmi Pharmaceutical has been assessed as having demonstrated its R&D competitiveness through a recent technology transfer. In response, some securities firms raised their target prices for the company. The company is managing the progress of further development based on the relevant contract terms.
Hyundai Motor said its collaboration with Boston Dynamics had entered a phase of taking shape. Some securities firms, reflecting this news, set a target price for Hyundai Motor at 100ten thousand won. The company said it was checking the scope and progress of the collaboration.
The outlook for Hyundai Mobis’s actuator business has been assessed as promising. Accordingly, some securities firms raised their target prices for Hyundai Mobis. The company continues to invest in the related business segment.
5Hyundai Motor and Kia had mixed results in monthly sales. Hyundai Motor’s sales were sluggish due to the impact of supply shortages for some parts. Kia performed relatively well as demand for eco-friendly vehicles increased.
Neurophet has obtained an international information security competitiveness certification. The company expects the certification to enhance trust in its products and services. The certification reflects the verification of its information security systems and procedures against external standards.
Securities firm reports and company announcements have been released in recent days. Details of collaborations among the companies involved, the terms of technology transfer agreements, and items to be checked in next quarter’s earnings announcements remain key disclosure matters. Investment decisions will be based on the disclosed contract terms and whether they are reflected in earnings.